

Applicant: Co. [redacted] et al.
Serial No.: Not yet assigned
Filed: Herewith
Page 4

25. (New) A compound according to Claim 11, wherein R11 or R12 contains from 1 to 5 heteroatoms selected from the group consisting of: sulphur, oxygen and nitrogen.

A²

26. (New) A compound according to Claim 12, wherein the ring contains a further nitrogen atom that is non-substituted or is substituted by a methyl or ethyl group.

27. (New) A compound according to Claim 14, wherein R14 is an alkylene radical with from 2 to 4 carbon atoms.

REMARKS

All of the claims have been amended herein to more clearly and specifically describe Applicants' invention. Entry of this amendment is respectfully requested. New claims have also been added. Support for the new claims is found in the application and claims as originally filed. No new matter is added. Entry of the new claims, and consideration of the application, is respectfully requested.


It is respectfully submitted that this application is now in condition for consideration and examination on the merits. If resolution of any remaining issue is required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' undersigned attorney at the telephone number provided below.

10030061 010402

Applicant: Co  et al.
Serial No.: Not yet assigned
Filed: Herewith
Page 5

No fee is required in connection with the filing of this Preliminary Amendment. If any fee is deemed necessary, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 11-0171.

Respectfully submitted,



John J. Santalone
Registration No.: 32,794
Attorney for Applicants

Kalow & Springut LLP
Telephone No.: (212) 813-1600

t:\patents\applications\13170\20011228 preliminary amendment.doc

10030061-016406

PATENT

10/030061

13170PCTUS

531 Rec'd PCT

04 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith

Examiner: Not yet assigned
Group Art Unit: Not yet assigned

For: Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

January 4, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

In accordance with 37 CFR § 1.121(c)(1)(ii) applicants submit the following marked-up version of claims corresponding to the amended claims filed herewith:

2. (Amended) [Compounds]A compound according to Claim 1, [in which]wherein R2 and R5 are identical to one another.
3. (Amended) [Compounds]A compound according to Claim 1[or Claim 2], [in which]wherein R3 and R6 are identical to one another.
4. (Amended) [Compounds]A compound according to [any one of Claims 1 to 3]Claim 1, [in which]wherein R1 is a saturated or mono-unsaturated alkyl radical with from 1 to 23 carbon atoms[, preferably from 13 to 15 carbon atoms].
5. (Amended) [Compounds]A compound according to [any one of Claims 1 to 4]Claim 1, [in which]wherein R4 is a saturated or mono-unsaturated alkylene radical with from 1 to 20 carbon atoms[, preferably from 6 to 14 carbon atoms].

10030061.040402

Applicant: Co. [REDACTED] et al.
Serial No.: Not yet assigned
Filed: Herewith
Page 2

6. (Amended) [Compounds]A compound according to [any one of Claims 1 to 5]Claim 1, [in which]wherein R7, R8 and R9 are [an]alkyl or alkenyl [radial]radicals with from 1 to 7 carbon atoms[, preferably a methyl group].

7. (Amended) [Compounds]A compound according to [any one of Claims 1 to 6]Claim 1, [in which]wherein R10 is an alkyl radical with from 1 to 20 carbon atoms.

8. (Amended) [Compounds]A compound according to [any one of Claims 1 to 7]Claim 1, [in which]wherein R2 is an alkyl or alkenyl group with from 1 to 7 carbon atoms.

9. (Amended) [Compounds]A compound according to [any one of Claims 1 to 8]Claim 1, [in which]wherein Y is an alkylene radical with from 2 to 20 carbon atoms[, preferably from 2 to 6 carbon atoms].

10. (Amended) [Compounds]A compound according to [any one of Claims 1 to 9]Claim 1, wherein[, in which, when] X is a cycloalkyl-ether or thio-ether, [it has]having a ring with 5 or 6 members[, preferably selected from tetrahydropyran-2-yl, tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl, tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl, or 1,4-dioxan-2-yl].

11. (Amended) [Compounds]A compound according to [any one of Claims 1 to 10]Claim 1, [in which]wherein R11 or R12 [are]is an alkyl or alkenyl radical with from 1 to 25 carbon atoms[possibly containing from 1 to 5 heteroatoms selected from sulphur, oxygen and nitrogen].

12. (Amended) [Compounds]A compound according to [any one of Claims 1 to 11]Claim 1, [in which]wherein R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members[, possibly containing a further nitrogen atom which is non-substituted or is substituted by a methyl or ethyl group].

10030061-010403

Applicant: Co *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 3

13. (Amended) [Compounds]A compound according to [any one of Claims 1 to 12]Claim 1, [in which]wherein the -NR¹²R¹³ group is selected from the group consisting of: piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl and hydroxyethylpiperazinyl groups.

14. (Amended) [Compounds]A compound according to [any one of Claims 1 to 13]Claim 1, [in which]wherein R¹⁴ is an alkylene radical with from 1 to 10 carbon atoms[, preferably from 2 to 4 carbon atoms].

15. (Amended) [Compounds]A compound according to [any one of Claims 1 to 14]Claim 1, [in which]wherein R¹⁵ is an alkyl or alkenyl radical with from 1 to 7 carbon atoms.

16. (Amended) [Compounds]A medicament comprising the compound according to [any one of Claims 1 to 15 for use as medicaments]Claim 1.

17. (Amended) [Compounds according to Claim 16, for use as]A drug[s] with agonist activity in relation to [the]a CB₂ cannabinoid receptor[s] comprising the compound according to Claim 16.

18. (Amended) [Compounds according to Claim 17, for use, alone or in association with functional agonists of the peripheral CB₁ receptor, as]A drug[s] for the treatment of inflammatory processes[, and also those] or inflammatory processes with a hyperalgetic component, each process having [both with]a neurogenic basis [and with]or an immunogenic basis, each basis being associated with a immuno-inflammatory [and]condition, a neurodegenerative pathological condition[s and], or a pathological condition[s] in which a non-psychomimetic effect of cannabinoids mediated either by CB₂ receptors or by peripheral CB₁ receptors is noted.

19. (Amended) A cosmetic additive comprising [Use of] the compound[s] according to [anyone of]Claim[s] 1[to 15 as cosmetic additives].

100300001.010400